Updated hourlyHourly refreshMon, Oct 26, 2026
AI · SaaS
Boca Raton, Florida Monday Oct 12, 2026 @ 5:00 AM Eastern —
DuLac Farmaceutici is following up with prospective retail and distribution partners after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida.
This event is marking another step in the Italian pharmaceutical company's effort to build a broader U.S. retail presence beyond its established Amazon business.
The event provided an opportunity to discuss DuLac’s Italian-developed portfolio with buyers across health, specialty, food, drug and mass retail channels. The company is now continuing those conversations to explore product assortment and distribution opportunities in the United States.
DuLac’s portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines. The portfolio reflects the company’s Italian manufacturing expertise, botanical formulation capabilities, and more than 30 years of pharmaceutical industry experience.
Building on an Existing E-Commerce Presence
DuLac enters these discussions with products already available to U.S. consumers through its Amazon storefront and OneLavi.
Customer feedback provides an additional point of reference for prospective partners: The company’s Arnica Gel 98% listing on Amazon.com has an average customer rating of 4.5 out of 5 stars, offering prospective partners a reference point for consumer feedback as they evaluate the portfolio.
"Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels,” said Gabriele Bollani, Founder and CEO of DuLac Farmaceutici. “We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner’s commercial needs.”
Italian Expertise Behind the Portfolio
During the meetings, DuLac introduced buyers to the research and manufacturing approach behind its products, including its proprietary Arnica Montana Arricchita™ project and its work with botanical ingredients and advanced extraction technologies.
The company’s European pharmacy heritage and Italian production provide the foundation for its portfolio. Follow-up discussions will focus on the products relevant to each prospective partner, their positioning and the requirements for a potential launch.
U.S. Retail and Distribution Opportunities
Following ECRM, DuLac is continuing discussions with prospective partners to assess product assortment, channel fit and distribution opportunities, while building on its existing U.S. e-commerce presence.
The company's long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, combining its European pharmacy heritage and Italian manufacturing with the consumer traction it has already established in the American market.
About DuLac Farmaceutici
DuLac Farmaceutici is an Italian pharmaceutical company specializing in dermo-cosmetic products developed through pharmaceutical-grade manufacturing standards. Built on more than 30 years of pharmaceutical industry expertise, the company combines botanical innovation, advanced extraction technologies, and modern manufacturing to create Italian-developed products for international markets. DuLac products are developed and manufactured in Italy using rigorous quality and sustainability standards. Learn more at DuLac Farmaceutici USA, through the company's Amazon Storefront, and on OneLavi.
Oct 12 · 09:00·Newsworthy.ai
Energy · Retail
V-Guard Industries Limited, one of India’s leading consumer electrical and electronics brands, has announced its Diwali Dhamaka Sale 2026, running from October 8 to November 10, 2026, on the V-Guard website. The sale offers discounts of up to 63% on select products across key categories, including voltage stabilizers, water heaters, inverters and battery combos. Sale […]
Oct 12 · 07:35·Webnewswire
Finance · AI
Hong Kong, Oct 12, 2026 - Changzhou Microintelligence Co., Ltd (“Microintelligence” or “the Company”) recently passed the hearing of the Listing Committee of The Stock Exchange of Hong Kong Limited (HKEX) on X 2026. Orient Capital, the subsidiary of Orient Securities, is the sole sponsor for the initial public offering. Based on 2025 revenue, the Company is China’s largest supplier of Embodied Industrial Intelligent Robots (EIIR), with a market share of approximately 20.0%.
Microintelligence was founded in 2018. As a leader in industrial embodied intelligence, the Company develops EIIR products and integrated solutions capable of autonomous perception, learning, decision-making and executing of complex tasks with its full-stack self-developed software, hardware and systems engineering capabilities. Its products have achieved commercialization at scale in real-world industrial settings, including in industries with extremely high requirements for precision, stability, and reliability, such as 3C electronics, automotive manufacturing, new energy, fast-moving consumer goods (FMCG), and semiconductors. Meanwhile, its application scenarios are evolving from "mature single-process workflow” to "integrated workstations." According to IDC's China Industrial Embodied Intelligent Robots Market Share, 2025 report, the company holds the No. 1 market share in China. The Company is also one of the world’s first leading companies to achieve commercial verification of embodied industrial intelligence robots in multiple complex industrial scenarios.
Through a standardized "Cloud-Edge-Device" integrated architecture, Microintelligence combines AI models, industrial know-how, and real-world scenario data to build core physical AI capabilities. This enables EIIR to complete a fully autonomous closed loop spanning perception, learning, decision-making, and execution. As EIIR systems roll out across real factory environments, the company has also built a "data-model-product-redeployment" flywheel. On-site data accumulated during production line operations is distilled into process knowledge through a "human-in-the-loop" mechanism with insights fed back into ongoing model iteration. As model capabilities advance, the products can take on more complex production tasks and continue to broaden their application scope. Backed by full-stack software and hardware capabilities and commercial validation in real-world scenarios, the company has delivered efficient, cost-effective commercialisation across multiple industrial scenarios, creating a durable competitive moat.
Through the continuous deployment of the aforementioned technologies and industrial practices, the Company has been accumulating real production-line industrial data while maintaining high levels of R&D investment. According to the documents disclosed after its hearing, the Company amassed an unstructured, finely-annotated database sourced from real industrial scenarios, with a data volume exceeding 23TB and containing over 1.6 billion annotated data records. The database holds more than 800 independent intellectual property rights, including over 210 invention patents and 310 software copyrights. In 2024, the Company’s R&D project entitled “Development and Application of High-Speed, Self-Planning, Integrated Intelligent System for Defect Detection and Repair” has been jointly certified by the Ministry of Industry and Information Technology (MIIT) and the Ministry of Science and Technology (MOST) as having reached an “International Leading” level. The Company’s client base includes more than 25 Fortune Global 500 enterprises and leading manufacturers. Its business spans mainland China, Europe and the United States, and actively develops for the expansion into new overseas markets including Japan, Singapore and Malaysia.
Financially, the Company’s revenue rose from RMB 434 million in 2023 to RMB 796 million in 2025, representing a compound annual growth rate (CAGR) of 35.4%. For the five months ended May 31, 2026, the Company recorded revenue of RMB 424 million, up 22.6% year on year. Revenue from its flagship EIIR products grew from RMB 114 million in 2023 to RMB 453 million in 2025, and reached RMB 260 million for the five months ended May 31, 2026. The EIIR products’ contribution to total revenue rose to 61.4% for the five months ended May 31, 2026, while gross margin further improved to 54.8%.
In terms of profitability, the Company achieved profitable results for two consecutive years in 2024 and 2025. It recorded a full-year profit of approximately RMB 15.7 million in 2024 and approximately RMB 5.1 million in 2025, as higher R&D investment weighed on profit for the year. For the five months ended May 31, 2026, profit reached RMB 22.53 million, while adjusted net profit for the period—excluding the impact of share-based payments and listing expenses—amounted to RMB 33.84 million, up 41.5% year on year. In addition, following the turnaround to positive operating cash flow in 2025, the Company continued to record net cash inflow for the five months ended May 31, 2026, reflecting a substantive and sustained improvement in the cash-generating capability of its core business.
The Company plans to primarily allocate the proceeds from this initial public offering to core technology R&D, focusing on iterating the Company’s end-to-end industrial VLA model, to continuously enhance the intelligence and performance of EIIR robots. In parallel, the Company will build localised overseas sales and service networks to deepenits global business footprint. In addition, the Company will allocate the proceeds for strategic investments and to foster an open, win-win application ecosystem through M&A, to expand manufacturing capacity to meet the growing order volumes.
Looking ahead, Microintelligence will seize the opportunity presented by its HKEX listing to continue to strengthen its core capabilities in industrial embodied intelligence. As the global manufacturing sector continues to advance its intelligent transformation, the Company will focus on six key dimensions—deepening customer engagement, replicating success across new industries, expanding overseas, upgrading product value, strengthening software-hardware synergies, and driving continuous AI evolution—to bring EIIR solutions into more industrial scenarios. Together with industry partners, the Company will build an industrial embodied intelligence ecosystem and create long-term value for customers and the industry as a whole.
Oct 12 · 04:20·ACN Newswire
Retail · Gaming
HONG KONG, Oct. 11, 2026 -- Phase I of the October 2026 Global Sources Hong Kong Shows opened today at AsiaWorld-Expo, running from October 11 to 14. Under the theme "Connecting Global Innovation, Enabling Sustainable Sourcing," the Consumer Electronics Show and Gaming Show...
Oct 11 · 10:09·PR Newswire
Retail
VANCOUVER, BC, Oct. 10, 2026 -- Wall Street Investor News Commentary - Four publicly listed retail investing platforms now report more than 41 million funded accounts between them, and two of them reported record quarters this summer. The pattern is the same across all of...
Oct 10 · 18:06·PR Newswire
Retail
SHENZHEN, China, Oct. 10, 2026 -- Arrvel is expanding its label printing portfolio with thermal printing solutions designed to support e-commerce sellers, small businesses, and everyday labeling needs. Combining compact designs with practical functionality, Arrvel's label...
Oct 10 · 15:11·PR Newswire
Retail
CHICAGO and VANCOUVER, British Columbia, Oct. 10, 2026 -- RISE Dispensaries, an industry-leading cannabis retail chain owned by Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), today announced the opening of RISE Dispensary Cape Coral, Florida, on October 10. Located at 928 NE Pine Island Road, RISE Dispensary Cape Coral is Green Thumb’s 25th retail location in Florida, adding to the Company’s network of more than 120 stores nationwide.
Oct 10 · 11:00·GlobeNewswire
Retail
WASHINGTON, Oct. 9, 2026 -- The U.S. Consumer Product Safety Commission (CPSC) is urging those in the path of Hurricane Isaias to take steps to protect themselves and their families against carbon monoxide (CO) poisoning, fires and other post-storm hazards. Hurricane Isaias,...
Oct 9 · 20:56·PR Newswire
Retail
Consumer products veteran to lead the nutribullet® and magic bullet® business. LOS ANGELES, Oct. 9, 2026 -- Capital Brands, the marketer of nutribullet® and magic bullet® small appliances, announced the appointment of Steve Baram as Chief Executive Officer, effective...
Oct 9 · 20:53·PR Newswire
AI · SaaS
Boca Raton, Florida Friday Oct 9, 2026 @ 3:00 PM Eastern —
Green Choice Proteins, an Australian plant-based nutrition company preparing to expand into the United States, is highlighting an evolving approach to plant-based eating as consumers increasingly look beyond meat alternatives toward convenient, protein-rich foods and everyday nutrition products.
Plant-based nutrition is no longer defined solely by consumers following vegan or vegetarian diets. Interest in incorporating more plant-derived ingredients into everyday meals has broadened the conversation to include protein content, ingredient transparency, flavor and convenience.
For Green Choice Proteins, this evolution reflects the philosophy behind its Australian-made plant protein products, which are designed for consumers seeking practical ways to incorporate plant-based nutrition into their daily routines.
"Plant-based nutrition doesn't have to be an all-or-nothing lifestyle choice," said Puneet Chawla, Founder of Green Choice Proteins. "We believe consumers should have access to high-quality plant protein products that fit naturally into their everyday lives, whether they're focused on fitness, general wellness or simply making more thoughtful food choices."
Moving Beyond Traditional Plant-Based Categories
As plant-based nutrition continues evolving, consumers have more options beyond products designed to replace meat or dairy. Plant proteins can also serve as convenient ingredients in smoothies, breakfast foods, baking and other everyday meals.
Green Choice Proteins focuses on this broader approach, combining plant-derived protein with carefully selected ingredients and flavors designed to make everyday nutrition both convenient and enjoyable.
The company's formulations feature Australian-grown pea and faba proteins, omega-3 from linseed and no artificial colours, flavours or fillers.
Three Flavors Designed for Everyday Nutrition
Green Choice Proteins' initial U.S. product lineup includes three plant-based protein powders:
Chocolate Flavored Protein Powder - Plant-Based Protein
35.3g plant protein per serving
Made with Australian-grown pea and faba
Features pure cocoa powder and coconut milk powder
Contains omega-3 from linseed
No artificial colours, flavours or fillers
Vanilla Flavored Protein Powder - Plant Based Protein
34.9g plant protein per serving
Designed for smoothies, oats, baking and everyday nutrition routines
Made using Australian-grown plant proteins
Includes omega-3 from linseed
Clean vanilla flavor profile without artificial additives
Salted Caramel Flavored Protein Powder - Plant Based Protein
34.9g plant protein per serving
Combines caramel sweetness with balanced salted notes
Made using Australian-grown pea and faba
Includes omega-3 from linseed
No artificial colours, flavours or fillers
"Taste and convenience are just as important as the nutritional profile," added Chawla. "Our goal is to create products that people genuinely enjoy incorporating into their routines. We want plant-based nutrition to feel accessible and practical, not complicated or restrictive."
Australian-Made Nutrition With a Focus on Transparency
Manufactured in Victoria, Australia, Green Choice Proteins emphasizes ingredient transparency, responsible sourcing and clean-label formulations.
The family-owned company uses Australian-grown pulses as a foundation for its products while incorporating other thoughtfully selected ingredients to create its plant protein formulations.
Green Choice Proteins believes the growing interest in everyday plant-based nutrition creates opportunities for brands that can combine quality ingredients with enjoyable flavors and convenient formats.
Building a Presence in the United States
The company's focus on everyday plant nutrition comes as Green Choice Proteins continues its U.S. expansion strategy.
Following its participation in September's ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, the company is preparing to introduce its products to American consumers through OneLavi and Amazon.
The upcoming launches represent the initial stages of Green Choice Proteins' broader strategy to establish its Australian-made plant nutrition products in the United States.
For more information, visit Green Choice Proteins.
About Green Choice Proteins
Based in Victoria, Australia, Green Choice Proteins is a family-owned plant-based nutrition company focused on delivering clean, functional daily nutrition for modern lifestyles. Using plant proteins derived from Australian-grown crops and manufacturing its products in Victoria, the company combines high-quality plant protein with thoughtfully selected functional ingredients to support everyday wellness, performance, and recovery. Built on a philosophy of transparency, sustainability, and formulation integrity, Green Choice Proteins creates clean-label nutrition products with no artificial colours, flavours, or fillers, helping consumers simplify their wellness routines with trusted, Australian-made plant-based nutrition.
Follow Green Choice Proteins on Instagram and Facebook.
Oct 9 · 19:00·Newsworthy.ai
Finance · Healthcare
Aetna 2027 Star Ratings Reflect Strong Clinical Quality and Member Experience
Tue, 10/13/2026 - 08:15
Body
Originally published on CVS Health Company Newsroom
HARTFORD, Conn., October 13, 2026 - Aetna®, a CVS Health® company (NYSE: CVS), announced today that more than 69 percent of its Medicare Advantage (MA) members are in 2027 plans rated 4 stars or higher (out of 5 stars) by the Centers for Medicare & Medicaid Services (CMS). These results position Aetna as one of the highest-performing large, publicly traded Medicare Advantage organizations in the Star Ratings program for the third consecutive year and highlight strong performance across various clinical quality, preventive care and member experience measures.
"For years, Aetna has been a leader in Star Ratings, and this year's results highlight our distinction in the market," said Steve Nelson, President of Aetna. "We continue to strengthen our business through an unwavering focus on the fundamentals and disciplined execution, and we are encouraged by our performance in areas like clinical quality and operational excellence. This focus gives us confidence in our ability to achieve our goal of returning to appropriate margins while at the same time driving continuous improvement and delivering even better experiences and outcomes for the members who count on us.
Outstanding clinical quality performance
Our 2027 Star Ratings results demonstrate excellence across several key clinical quality measures.
Aetna achieved an outstanding score on Plan All-Cause Readmissions (4.77* out of 5 stars), showcasing the strength of our care coordination programs, provider partnerships and focus on helping members successfully transition between care settings. Keeping members out of the hospital is one of the most important indicators of health care quality.
Our high-performing scores on Care for Older Adults Medication Review (5.00*) and Care for Older Adults Functional Status Assessment (4.03*) demonstrate the support we provide members in managing their health and maintaining their independence.
Reinforcing our commitment to early detection and preventive care, we earned strong scores on preventive screening measures, including Colorectal Cancer Screening (4.19*) and Breast Cancer Screening (4.07*).
Delivering a high-quality member experience
Aetna also delivered exceptional results on measures related to member experience and the quality of our customer support.
Low rates of Complaints about the Drug Plan (4.29*) demonstrate members' confidence in our service and commitment to resolving issues quickly and effectively.
Strong performance on Customer Service (4.04*), Getting Needed Care (3.89*) and Getting Needed Prescription Drugs (4.07*) further highlight our focus on making health care easier to access and navigate.
Aetna earned a high score on Rating of Health Care Quality (4.22*), indicating the positive experiences members had with their health care providers and the broader care experience supported by Aetna.
In addition, we demonstrated operational excellence through outstanding performance in service and administrative measures, including Call Center Foreign Language Interpreter and Teletypewriter Availability (4.99*), Reviewing Appeals Decisions (4.08*), Plan Makes Timely Decisions About Appeals (4.01*) and Drug Price Accuracy (4.01*). These results underscore our commitment to providing accurate information, fair processes, timely decisions and accessible support for every member.
Every year, Medicare evaluates plans based on a 5-star rating system. The Star Ratings are posted at Medicare.gov. Visit AetnaMedicare.com to learn more about the 2027 Aetna Medicare plans. Or call 1-844-588-0041 (TTY: 711), 7 days a week, 8 AM to 8 PM. The Medicare Annual Enrollment Period runs from October 15 through December 7, 2026. A licensed agent may answer your call.
NOTE: Information in this release is based on 2027 Star Ratings data published by CMS on October 8, 2026, and MA and MAPD enrollment as of September 2026. Individual plan ratings may vary.
*FOR STAR RATING MEASURE SCORES: All scores are based on a rating scale of five stars.
About CVS Health
CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of June 30, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
About Aetna
Aetna, a CVS Health business, serves an estimated 37 million people with information and resources to help them make better informed decisions about their health care. Aetna offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, and medical management capabilities, Medicaid health care management services, workers' compensation administrative services and health information technology products and services. Aetna's customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups and expatriates. For more information, visit Aetna.com.
Aetna Medicare is a HMO, PPO plan with a Medicare contract. Our SNPs also have contracts with State Medicaid programs. Enrollment in our plans depends on contract renewal. See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area.
To send a complaint to Aetna, call the Plan or the number on your member ID card. To send a complaint to Medicare, call 1-800-MEDICARE (TTY users should call 1-877-486-2048), 24 hours a day/7 days a week. If your complaint involves a broker or agent, be sure to include the name of the person when filing your grievance.
©2026 Aetna Inc.
Media contact
Phil Blando
Phillip.blando@cvshealth.com
Investor contact
Larry McGrath
800-201-0938
InvestorInfo@CVSHealth.com
Y0001_9425651a_2027_M
Featured Image
Type of Content
Press Release
Oct 9 · 18:31·3BL Media
AI · Retail
PALO ALTO, Calif., October 09, 2026--Nectar, the agentic growth operating system connecting businesses to consumers, today launched Nectar MCP, which connects a brand's Nectar data to ChatGPT, Claude, Gemini and Copilot. It is built on the Model Context Protocol, the open standard AI assistants use to connect to outside data.
Oct 9 · 17:30·Business Wire